The Top 5 Biosimilars Articles for the First Half of 2019

The Center for Biosimilars® recaps the 5 most-read stories of 2019 to date.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

It’s been a busy year for biosimilars, and this week, we’re recapping the 5 most-read stories of 2019 to date.

Number 5: The year opened with price hikes to a number of prescription drugs.

Number 4: The FDA approved another biosimilar trastuzumab product referencing Herceptin.

Number 3: Biosimilar developer Pfizer confirmed that it had cut 5 preclinical biosimilar programs from its portfolio.

Number 2: The FDA released its long-awaited final guidance on demonstrating interchangeability.

Number 1: The FDA approved Samsung Bioepis’ trastuzumab biosimilar.

What will the second half of the year hold for biosimilars? Stay up to date with the key news as it unfolds at